Effects of Hypernatremia on the Microglia.

NaCl arginine vasopressin hypernatremia microglia minocycline nuclear factor of activated T-cells 5 osmotic demyelination syndrome

Journal

Peptides
ISSN: 1873-5169
Titre abrégé: Peptides
Pays: United States
ID NLM: 8008690

Informations de publication

Date de publication:
20 Jun 2024
Historique:
received: 26 02 2024
revised: 07 06 2024
accepted: 19 06 2024
medline: 23 6 2024
pubmed: 23 6 2024
entrez: 22 6 2024
Statut: aheadofprint

Résumé

Signs and symptoms of hypernatremia largely indicate central nervous system dysfunction. Acute hypernatremia can cause demyelinating lesions similar to that observed in osmotic demyelination syndrome (ODS). We have previously demonstrated that microglia accumulate in ODS lesions and minocycline protects against ODS by inhibiting microglial activation. However, the direct effect of rapid rise in the sodium concentrations on microglia is largely unknown. In addition, the effect of chronic hypernatremia on microglia also remains elusive. Here, we investigated the effects of acute (6 or 24h) and chronic (the extracellular sodium concentration was increased gradually for at least 7 days) high sodium concentrations on microglia using the microglial cell line, BV-2. We found that both acute and chronic high sodium concentrations increase NOS2 expression and nitric oxide (NO) production. We also demonstrated that the expression of nuclear factor of activated T-cells-5 (NFAT5) is increased by high sodium concentrations. Furthermore, NFAT5 knockdown suppressed NOS2 expression and NO production. We also demonstrated that high sodium concentrations decreased intracellular Ca

Identifiants

pubmed: 38908517
pii: S0196-9781(24)00120-7
doi: 10.1016/j.peptides.2024.171267
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

171267

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interest None

Auteurs

Sachiho Fuse (S)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Haruki Fujisawa (H)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Naoya Murao (N)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Naoko Iwata (N)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Takashi Watanabe (T)

Fujita Cancer Center, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Yusuke Seino (Y)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Hideyuki Takeuchi (H)

Department of Neurology and Stroke Medicine, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, 236-0004 Japan; Department of Neurology, Graduate School of Medicine, International University of Health and Welfare, Narita, Chiba, 286-8686 Japan; Center for Intractable Neurological Diseases and Dementia, International University of Health and Welfare Atami Hospital, Atami, Shizuoka, 413-0012 Japan.

Atsushi Suzuki (A)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan.

Yoshihisa Sugimura (Y)

Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, 470-1192 Japan. Electronic address: sugiyosi@fujita-hu.ac.jp.

Classifications MeSH